EMEA accepts Xiaflex MAA

EMEA accepted for filing an MAA from Pfizer Inc. (NYSE:PFE) for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture, a condition that affects the joints in the hand. The acceptance triggers a $15 million milestone payment to Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL), which granted Pfizer rights in the EU. Auxilium has worldwide rights from BioSpecifics Technologies Corp. (NASDAQ:BSTC), which will receive a $1.2 million portion of Auxilium's milestone payment. ...